InMed Pharmaceuticals Inc. Balance Sheet
INM|4 years of annual SEC 10-K data (FY2022-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
InMed Pharmaceuticals Inc. had $16M in total assets and $9M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash & Equivalents | $11.1M | $6.6M | $8.9M | $7.4M |
| Accounts Receivable | $465.1K | $352.8K | $260.4K | $88.0K |
| Inventory | $961.2K | $1.2M | $1.6M | $2.5M |
| Current Assets | $12.9M | $8.7M | $11.3M | $9.6M |
| PP&E (Net) | $992.2K | $1.2M | - | $904.3K |
| Total Assets | $15.6M | $11.8M | $14.1M | $12.8M |
| Current Liabilities | $1.8M | $2.0M | $2.0M | $3.3M |
| Shareholders' Equity | $9.2M | $12.1M | $9.1M | $7.4M |